Email Alert RSS
Volume 13 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. DOI: 10.12290/xhyxzz.2022-0584
Citation: Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. DOI: 10.12290/xhyxzz.2022-0584
shu

Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-C-028

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-010

CAMS Innovation Fund for Medical Sciences 2022-I2M-JB-001

More Information
  • Received Date: October 08, 2022
  • Accepted Date: October 24, 2022
  • Available Online: November 06, 2022
  • Issue Publish Date: November 29, 2022
    Graphical Abstract
    • Abstract
  • Subtype classification of primary aldosteronism is important but challenging. Increasing evidence has shown that 68Ga-Pentixafor PET/CT imaging which targets CXCR4 is beneficial to the subtype classification of primary aldosteronism. Based on all the available evidence, and after in-depth discussion of a group of multi-disciplinary experts, a consensus has been established, which covers imaging technology, interpretation of results of CXCR4 imaging, and the guidance to the choice of the treatment and prognosisevaluation. The consensus is helpful for standardizing 68Ga-Pentixafor PET/CT imaging and promoting a better diagnosis procedure in primary aldosteronism.
    • FullText(HTML)
    • References (15)
  • [1]
    Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2016, 101: 1889-1916. DOI: 10.1210/jc.2015-4061
    [2]
    Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension[J]. J Hypertens, 2020, 38: 1919-1928. DOI: 10.1097/HJH.0000000000002510
    [3]
    Wang H, Wang F, Zhang Y, et al. Surgical Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings[J]. Front Endocrinol (Lausanne), 2021, 12: 663096. DOI: 10.3389/fendo.2021.663096
    [4]
    Mulatero P, Sechi LA, Williams T A, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension[J]. J Hypertens, 2020, 38: 1929-1936. DOI: 10.1097/HJH.0000000000002520
    [5]
    Walenkamp A, Lapa C, Herrmann K, et al. CXCR4 Ligands: The Next Big Hit?[J]. J Nucl Med, 2017, 58: 77S-82S. DOI: 10.2967/jnumed.116.186874
    [6]
    Heinze B, Fuss CT, Mulatero P, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma[J]. Hypertension, 2018, 71: 317-325. DOI: 10.1161/HYPERTENSIONAHA.117.09975
    [7]
    Ding J, Zhang Y, Wen J, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 2656-2665. DOI: 10.1007/s00259-020-04722-0
    [8]
    Ding J, Tong A, Zhang Y, et al. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using (68)Ga-Pentixafor[J]. J Nucl Med, 2022, 63: 368-375. DOI: 10.2967/jnumed.121.261964
    [9]
    Ding J, Tong A, Zhang Y, et al. Intense 68Ga-Pentixafor Activity in Aldosterone-Producing Adrenal Adenomas[J]. Clin Nucl Med, 2020, 45: 336-339. DOI: 10.1097/RLU.0000000000002946
    [10]
    Gao Y, Ding J, Cui Y, et al. Functional nodules in primary aldosteronism: identification of CXCR4 expression with (68)Ga-Pentixafor PET/CT[J]. Eur Radiol, 2022. doi: 10.1007/s00330-022-09058-x.
    [11]
    Song Y, Yang J, Shen H, et al. Development and validation of model for sparing adrenal venous sampling in diagnosing unilateral primary aldosteronism[J]. J Hypertens, 2022, 40: 1692-1701. DOI: 10.1097/HJH.0000000000003197
    [12]
    Fu B, Zhang X, Wang GX, et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma[J]. J Urol, 2011, 185: 1578-1582. DOI: 10.1016/j.juro.2010.12.051
    [13]
    中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36: 727-736. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202111003.htm

    Chinese Society of Endocrinology. Expert consensus on the diagnosis and treatment of primary aldosteronism (2020)[J]. Zhonghua Neifenmi Daixie Zazhi, 2020, 36: 727-736. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202111003.htm
    [14]
    Steichen O, Zinzindohoué F, Plouin PF, et al. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review[J]. Horm Metab Res, 2012, 44: 221-227. DOI: 10.1055/s-0031-1299681
    [15]
    Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort[J]. Lancet Diabetes Endocrinol, 2017, 5: 689-699. DOI: 10.1016/S2213-8587(17)30135-3
    • Related Articles

  • Related Articles

    [1]ZHAO Lidan, MENG Xia, XU Haojie, ZHANG Fengchun. Prospect of Gut Microbiota-based Intervention in Autoimmune Disease Control[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 740-746. DOI: 10.12290/xhyxzz.2022-0245
    [2]HUANG Ziyu, ZUO Tao, LAN Ping. Gastrointestinal Diseases and Gut Microbiome Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 732-739. DOI: 10.12290/xhyxzz.2022-0208
    [3]SU Pengfei, YU Jianchun. Progress in the Research on the Role of Tumor-associated Macrophages in Drug-resistance and Treatment of Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 480-486. DOI: 10.12290/xhyxzz.2021-0605
    [4]YANG Jingyi, XU Qianyue, YU Hong. Research Progress on Pathogenesis and Treatment of Juvenile Localized Scleroderma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(1): 110-116. DOI: 10.12290/xhyxzz.2021-0178
    [5]Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555
    [6]WANG Shi-rui, CHEN Shi, ZHU Hui-juan. Evaluation and Treatment of Coronavirus Disease 2019 with Obesity[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 13-17. DOI: 10.12290/xhyxzz.20200244
    [7]CAO Wei, LI Tai-sheng. Treatment of Coronavirus Disease 2019: Timing Determines Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 5-8. DOI: 10.3969/j.issn.1674-9081.2021.01.002
    [8]Zhi-tong GE, Jian-chu LI. Application of Ultrasonic Intervention in the Treatment of Vascular Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 62-67. DOI: 10.3969/j.issn.1674-9081.20190210
    [9]Xixojun MA. Overview of Diagnosis and Treatment of Infectious Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 393-398. DOI: 10.3969/j.issn.1674-9081.2018.05.003
    [10]Cheng XUE, Chen-chen ZHOU, Chang-lin MEI. Prognostic Evaluation and Treatment of Autosomal Dominant Polycystic Kidney Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 75-80. DOI: 10.3969/j.issn.1674-9081.2018.01.014

  • Cited by

    Periodical cited type(4)

    1. 陈瑞飞，史冬梅. 2017-2021年微生物学领域全球研究现状及主要国家对比. 科技和产业. 2024(01): 239-246 .
    2. 路小轩，孙之中. 基于《内经》“大肠者，皮其应”理论探讨痤疮与肠道菌群的关系. 中国民族民间医药. 2023(08): 14-17 .
    3. 吴丹，王立霞，杨苗苗，任彩霞，李白存，徐文. 维生素A对肠道屏障及其相关疾病的影响——以肠道感染性疾病和孤独谱系障碍为例. 保鲜与加工. 2022(12): 85-91 .
    4. 王楠楠，戴鼎震，郭宇飞，方光远，张萍，蒋加进. 《兽医微生物学》课程思政改革的探索与实践. 国外畜牧学(猪与禽). 2022(06): 97-101 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1309) PDF downloads (503) Cited by(7)
    Related
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

      Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return
      x Close Forever Close